Palabras clave
Guía de práctica clínica
Biomarcador
Tratamiento biológico
Resumen
Antecedentes: El asma sigue siendo una patología respiratoria crónica frecuente en México. Se han descrito nuevos métodos para el diagnóstico y tratamiento conforme se renuevan las guías internacionales.
Objetivo: Crear la plataforma nacional Manejo Integral del Asma (MIA), para el desarrollo de lineamientos actualizados con base en evidencia.
Métodos: Se utilizó el método ADAPTE. El grupo de desarrollo de MIA estuvo integrado por expertos en neumología, alergología y metodología y representantes de 13 instituciones y sociedades de especialidades que manejan asma. Las guías internacionales de referencia (seleccionadas con AGREE-II) fueron GINA 2020, GEMA 5.0, BTS/SIGN 2019 y consenso ATS/ERS 2014-2019. En MIA se aborda sospecha de asma, diagnóstico, tratamiento y grupos especiales. Se formularon preguntas clínicas clave sobre tratamiento en los pasos 1 a 3, biomarcadores y asma grave.
Resultados: Con base en evidencia, seguridad, costo y realidad local, el grupo nuclear desarrolló respuestas. Mediante proceso Delphi, el grupo amplio de desarrollo sugirió ajustes hasta que se logró el consenso.
Conclusión: El documento generado contiene múltiples figuras y algoritmos, está sólidamente basado en evidencia acerca del manejo del asma y fue ajustado para México con participación de diferentes sociedades para su desarrollo; no se incluyeron lineamientos para la crisis asmática.
Referencias
worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094 DOI: 10.1183/13993003.02094-2020
Carrillo G, Méndez-Domínguez N, Datta-Banik R, Figueroa-López F, Estrella-Chan B, Álvarez-Baeza A, et al. Asthma mortality and hospitalizations in Mexico from 2010 to 2018: retrospective epidemiologic profile. Int J Environ Res Public Health. 2020;17(14):5071. DOI: 10.3390/ijerph17145071
Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma: GUIMA 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. DOI: 10.29262/ram.v64i0.272
Tratamiento del asma en edad pediátrica. Guía de Práctica Clínica: evidencias y recomendaciones [Internet]. México: Centro Nacional de Excelencia Tecnológica en Salud; 2020. Disponible en: http://www.cenetec-difusion.com/CMGPC/GPC-SS-009-20/ER.pdf
SIGN 158. British Guideline on the Management of Asthma. A national clinical guideline [Internet]. Reino Unido: British Thoracic Society/National Health Service Scotland; 2019. Disponible en: https://www.brit-thoracic.org.uk/document-library/guidelines/asthma/btssign-guideline-for-the-management-of-asthma-2019/
Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention; 2019. Disponible en: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
GEMA 5.0. Guía Española para el Manejo del Asma [Internet]. España: Luzán 5; 2020. Disponible en: https://www.semg.es/images/documentos/GEMA_5.0.pdf
Holguín F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. DOI: 10.1183/13993003.00588-2019
Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-233. DOI: 10.1007/s12016-018-8712-1
Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018;10(1):34-45. DOI: 10.1080/19420862.2017.1392425
Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965-976. DOI: 10.1056/NEJMra1608969
Martínez-Briseño D, Gochicoa-Rangel L, Torre-Bouscoulet L, Cid-Juárez S, Fernández-Plata R, Martínez-Valdeavellano L, et al. Comparing spirometric reference values from childhood to old age estimated by LMS and linear regression models. Arch Bronconeumol. 2021;57(3):172-178. DOI: 10.1016/j.arbres.2019.12.033
Gochicoa-Rangel L, Vázquez-García J, Vargas-Domínguez C, Velázquez-Uncal M, et al. Bronchial challenge test with exercise: recommendations and procedure. Neumol Cir Torax. 2019;78(Suppl 2):S198-S211. Disponible en: https://www.medigraphic.com/pdfs/neumo/nt-2019/nts192m.pdf
Bedolla-Barajas M, Ortiz-Peregrina JR, Hernández-Colín DD, Morales-Romero J, Bedolla-Pulido TR, Larenas-Linnemann D. The characterization of asthma with blood eosinophilia in adults in Latin America. J Asthma. 2019;56(11):1138-1146. DOI: 10.1080/02770903.2018.1520863
Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452-456. DOI: 10.1183/09031936.00165106
O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19-24. DOI: 10.1164/rccm.200807-1126OC
Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-986. DOI: 10.1016/j.jaip.2017.12.019
Del Río-Navarro BE, Berber A, Reyes-Noriega N, Navarrete-Rodríguez EM, García-Almaraz R, Ellwood P, et al. Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study. BMJ Open Respir Res. 2020;7(1):e000658. DOI: 10.1136/bmjresp-2020-000658
Biagini-Myers JM, Schauberger E, He H, Martin LJ, Kroner J, Hill GM, et al. A Pediatric Asthma Risk Score to better predict asthma development in young children. J Allergy Clin Immunol. 2019;143(5):1803-1810. DOI: 10.1136/bmjresp-2020-000658
GEMA 4.0. Guía española para el manejo del asma. Arch Bronconeumol. 2015;51(Suppl 1):2-54. DOI: 10.1016/S0300-2896(15)32812-X
Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, del Río-Navarro BE, et al. Guía Mexicana del Asma: GUIMA 2017. Alerg Mex. 2017;64(Supl 1):s11-s128. DOI: 10.29262/ram.v64i0.272
Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis. 2010;5:311-318. DOI: 10.2147/copd.s12120
Van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9(8):1684-1688. DOI: 10.1183/09031936.96.09081684
Axelsson I, Naumburg E, Prietsch SO, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev. 2019;6(6):CD010126. DOI: 10.1002/14651858.CD010126.pub2
Agache I, Beltrán J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042. DOI: 10.1111/all.14221
Murphy KR, Hong JG, Wandalsen G, Larenas-Linnemann D, El Beleidy A, Zaytseva OV, et al. Nebulized inhaled corticosteroids in asthma treatment in children 5 years or younger: a systematic review and global expert analysis. J Allergy Clin Immunol Pract. 2020;8(6):1815-1827. DOI: 10.1016/j.jaip.2020.01.042
Martínez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650-657. DOI: 10.1016/S0140-6736(10)62145-9
Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, de Llano LP, et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142-152. DOI: 10.1089/jamp.2015.1212
Rodríguez-Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites. Rev Alerg Mex. 2008;55(2):71-75.
Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60(1):133. DOI: 10.1111/j.1398-9995.2004.00616.x
Larenas-Linnemann D, Luna-Pech JA, Rodríguez-Pérez N, Rodríguez-González M, Arias-Cruz A, Blandon-Vijil MV, et al. GUIMIT 2019, Guía Mexicana de Inmunoterapia. Guía de diagnóstico de alergia mediada por IgE e inmunoterapia aplicando el método ADAPTE. Rev Alerg Mex. 2019;66(Supl 1):1-105. DOI: 10.29262/ram.v66i5.631
Vrijlandt E, Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018;6(2):127-137. DOI: 10.1016/S2213-2600(18)30012-2
Parra-Padilla D, Zakzuk J, Carrasquilla M, Alvis-Guzmán N, Dennis R, Rojas MX, et al. Cost-effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: A mathematical model. Allergy. 2020. DOI: 10.1111/all.14723
Larenas-Linnemann D, Gochicoa-Rangel L, Macías-Weinmann A, Soto-Ramos M, Luna-Pech JA, Elizondo-Ríos A, et al. Consenso mexicano en relación con la fracción exhalada de óxido nítrico (FeNO) en asma 2020. Rev Alerg Mex. 2020;67(Supl 2):s1-s25. DOI: 10.29262/ram.v67i0.760
Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. DOI: 10.1016/j.jaci.2014.08.042
Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, et al. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir Res. 2018;19(1):12. DOI: 10.1186/s12931-018-0719-x
Richards LB, Neerincx AH, van Bragt J, Sterk PJ, Bel EHD, Maitland-van der Zee AH. Biomarkers and asthma management: analysis and potential applications. Curr Opin Allergy Clin Immunol. 2018;18(2):96-108. DOI: 10.1097/ACI.0000000000000426
Mogensen I, James A, Malinovschi A. Systemic and breath biomarkers for asthma: an update. Curr Opin Allergy Clinical Immunol. 2020;20(1):71-79. DOI: 10.1097/ACI.0000000000000599
Contreras-Omaña R, Sánchez-Reyes O, Ángeles-Granados E. Comparison of the Carlsson-Dent and GERD-Q questionnaires for gastroesophageal reflux disease symptom detection in a general population. Rev Gastroenterol Mex. 2017;82(1):19-25. DOI: 10.1016/j.rgmx.2016.05.005
Traister RS, Fajt ML, Landsittel D, Petrov AA. A novel scoring system to distinguish vocal cord dysfunction from asthma. J Allergy Clin Immunol Pract. 2014;2(1):65-69. DOI: 10.1016/j.jaip.2013.09.002
Amra B, Rahmati B, Soltaninejad F, Feizi A. Screening questionnaires for obstructive sleep apnea: an updated systematic review. Oman Med J. 2018;33(3):184-92. DOI: 10.5001/omj.2018.36
Bardin PG, Rangaswamy J, Yo SW. Managing comorbid conditions in severe asthma. Med J Aust. 2018;209(S2):S11-S17. DOI: 10.5694/mja18.00196
Lee SH, Ban GY, Kim SC, Chung CG, Lee HY, Lee JH, et al. Association between primary immunodeficiency and asthma exacerbation in adult asthmatics. Korean J Intern Med. 2020;35(2):449-456. DOI: 10.3904/kjim.2018.413
Keswani A, Dunn NM, Manzur A, Kashani S, Bossuyt X, Grammer LC, et al. The clinical significance of specific antibody deficiency (SAD) severity in chronic rhinosinusitis (CRS). J Allergy Clin Immunol Pract. 2017;5(4):1105-1111. DOI: 10.1016/j.jaip.2016.11.033
Berti A, Cornec D, Casal-Moura M, Smyth RJ, Dagna L, Specks U, et al. Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest. 2020;157(5):1086-1099. DOI: 10.1016/j.chest.2019.11.045
Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? Curr Opin Allergy Clin Immunol. 2019;19(1):46-52. DOI: 10.1097/ACI.0000000000000492
Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J. 2014;43(5):1487-1500. DOI: 10.1183/09031936.00139513
Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14(1):32-38. DOI: 10.1034/j.1399-3003.1999.14a08.x
Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35-46. DOI: 10.1007/BF00435967
Suehs CM, Menzies-Gow A, Price D, Bleecker ER, Canonica GW, Gurnell M, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma: a Delphi study. Am J Respir Crit Care Med. 2020;203(7):871-881. DOI: 10.1164/rccm.202007-2721OC
Alves C, Robazzi TC, Mendonca M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008;84(3):192-202. DOI:10.2223/JPED.1773
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615. DOI: 10.1164/rccm.9120-11ST
Panickar JR, Kenia P, Silverman M, Grigg J. Intramuscular triamcinolone for difficult asthma. Pediatr Pulmonol. 2005;39(5):421-425. DOI: 10.1002/ppul.20176
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. DOI: 10.1164/rccm.201208-1414OC
Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485-486. DOI: 10.1016/j.jaci.2013.02.032
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197. DOI: 10.1056/NEJMoa1403291
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207. DOI: 10.1056/NEJMoa1403290
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X
Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789-798. DOI: 10.1016/j.chest.2016.03.032
Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132. DOI: 10.1164/rccm.201103-0396OC
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Bruselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(4):355-366. DOI: 10.1016/S2213-2600(15)00042-9
Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799-810. DOI: 10.1016/j.chest.2016.03.018
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. DOI: 10.1016/S0140-6736(16)31322-8
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127. DOI: 10.4168/aair.2019.11.4.508
Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458. DOI: 10.1056/NEJMoa1703501
Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135-145. DOI: 10.1159/000444799
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44. DOI: 10.1016/S0140-6736(16)30307-5
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. DOI: 10.1056/NEJMoa1804093
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. DOI: 10.1056/NEJMoa1804092
Corren J, Castro M, O’Riordan T, Hanania NA, Pavord ID, Quirce S, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526. DOI: 10.1016/j.jaip.2019.08.050
Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790-804. DOI: 10.1016/j.chest.2019.10.053
Torrego A, Sola I, Muñoz AM, Roque IFM, Yepes-Núñez JJ, Alonso-Coello P, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014(3):CD009910. DOI: 10.1002/14651858.CD009910.pub2
Zhou JP, Feng Y, Wang Q, Zhou LN, Wan HY, Li QY. Long-term efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma: a systemic review and meta-analysis. J Asthma. 2016;53(1):94-100. DOI: 10.3109/02770903.2015
Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011;11:8. DOI: 10.1186/1471-2466-11-8
Álvarez-Gutiérrez F, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero J, Padilla A, et al. Consensus document for severe asthma in adults. 2020 update. Open Respir Arch. 2020;2(3):158-174. DOI: 10.1016/j.opresp.2020.03.005
Morales A. Bronchial thermoplasty - A new therapeutic tool for severe asthma. Rev Chil Enferm Respir. 2017;33:113-117. DOI: 10.4067/s0717-73482017000200113
Busse W, Bleecker ER, FitzGerald M, Ferguson GT, Barker P, et al. Three-year safety and efficacy of benralizumab for adolescent patients with severe, uncontrolled asthma: results of the BORA extension study. J Allergy Clin Immunol. 2020;145(Suppl 2):AB174. DOI: 10.1016/j.jaci.2019.12.363
Bonini M, di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137. DOI: 10.1183/16000617.0137-2019
Upham J, Le Lievre C, Jackson D, Masoli M, Wechsler M, Price D, et al. Defining a severe asthma super-responder: findings from a Delphi process [Internet]. Australia: Observational & Pragmatic Research Institute/The University of Queensland; 2020. Disponible en: https://opri.sg/wp-content/uploads/2020/08/Super_responders_poster_ERS.pdf
Erdogan T. Evaluating nonadherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab. Clin Respir J. 2020;14(12):1153-1158. DOI: 10.1111/crj.13252
Domingo C, Pomares X, Navarro A, Amengual MJ, Monton C, Sogo A, et al. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. Br J Clin Pharmacol. 2018;84(2):339-348. DOI: 10.1111/bcp.13453
Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56-60. DOI: 10.1111/j.1398-9995.2009.02144.x
Vennera MC, Sabadell C, Picado C, Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73(8):782-784. DOI: 10.1136/thoraxjnl-2017-210017
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate to severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560-567. DOI: 10.1016/j.jaci.2014.02.007
Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868-875. DOI: 10.1056/NEJM199503303321307
Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98(2):196-208. DOI: 10.1056/NEJM199503303321307
Kowalski ML, Wojciechowski P, Dziewonska M, Rys P. Adrenal suppression by inhaled corticosteroids in patients with asthma: a systematic review and quantitative analysis. Allergy Asthma Proc. 2016;37(1):9-17. DOI: 10.2500/aap.2016.37.3912
Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs. 1994;47(2):318-331. DOI: 10.2165/00003495-199447020-00007
Weatherall M, James K, Clay J, Perrin K, Masoli M, Wijesinghe M, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451-1458. DOI: 10.1111/j.1365-2222.2008.03029.x
Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904-912. DOI: 10.1056/NEJMoa1203229
Kong-Loke Y, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133428. DOI: 10.1371/journal.pone.0133428
Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14(7):983-990. DOI: 10.1111/j.1440-1843.2009.01589.x
Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-24. DOI: 10.1183/09031936.02.00269802
Sears MR. Adverse effects of -agonists. J Allergy Clin Immunol. 2002;110(Suppl 6):S322-S328. DOI: 10.1067/mai.2002.129966
Cullinan P, Vandenplas O, Bernstein D. Assessment and management of occupational asthma. J Allergy Clin Immunol Pract. 2020;8(10):3264-3275. DOI: 10.1016/j.jaip.2020.06.031
Baur X, Sigsgaard T, Aasen TB, Burge PS, Heederik D, Henneberger P, et al. Guidelines for the management of work-related asthma. Eur Respir J. 2012;39(3):529-545. DOI: 10.1183/09031936.00096111
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-681. DOI: 10.1016/j.jaci.2014.08.020
Mustafa SS, Vadamalai K, Scott B, Ramsey A. Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease. Am J Rhinol Allergy. 2020:1945892420961969. DOI: 10.1177/1945892420961969
Lailaw T, Mullol J, Canonica G, Bachert C, Han J, Zhang M, et al. Dupilumab improves upper and lower airway outcome measures in patients with CRSwNP with NSAID-ERD: pooled results from the SINUS-24 and SINUS-52 phase 3 trials. W Allergy Organ J. 2020;13(8)100398. DOI: 10.1016/j.waojou.2020.100398
Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):207. DOI: 10.1186/s12890-020-01248-x
Caruso C, Colantuono S, Pugliese D, Di Mario C, Tolusso B, Gremese E, et al. Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report. Allergy Asthma Clin Immunol. 2020;16:27. DOI: 10.1186/s13223-020-00423-3
Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J. 2017;47(6):623-631. DOI: 10.1111/imj.13441
Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008;121(5):1087-1093; quiz 1094-1095. DOI: 10.1016/j.jaci.2008.03.004
Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146(4):685-693. DOI: 10.1016/j.jaci.2020.08.011
Maniscalco M, Zedda A, Faraone S, Cerbone MR, Cristiano S, Giardiello C, et al. Weight loss and asthma control in severely obese asthmatic females. Respir Med. 2008;102(1):102-108. DOI: 10.1016/j.rmed.2007.07.029
Kuehn BM. Asthma linked to psychiatric disorders. JAMA. 2008;299(2):158-160. DOI: 10.1001/jama.2007.54-a
Espinosa-Leal FD, Parra-Román M, Méndez NH, Toledo-Nicolás DA, Menez-Díaz D, Sosa-Eroza E, et al. Ansiedad y depresión en asmáticos adultos en comparasión con sujetos sanos. Rev Alerg Mex. 2006;53(6):201-206.
Bedolla-Barajas M, Morales-Romero J, Fonseca-López JC, Pulido-Guillén NA, Larenas-Linnemann D, Hernández-Colín DD. Anxiety and depression in adult patients with asthma: the role of asthma control, obesity and allergic sensitization. J Asthma. 2020;1-9. DOI: 10.1080/02770903.2020.1759087
Oren E, Martínez FD. Stress and asthma: physiological manifestations and clinical implications. Ann Allergy Asthma Immunol. 2020;125(4):372-373.e1. DOI: 10.1016/j.anai.2020.07.022
Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med. 2005;99(9):1152-1159. DOI: 10.1016/j.rmed.2005.02.013
Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both? Chest. 2006;130(4):1039-1047. DOI: 10.1378/chest.130.4.1039
Sharrad K, Sanwo O, Carson-Chahhoud K, Pike K. Psychological interventions for asthma in children and adolescents. Cochrane Database Syst Rev. 2019;2019(9):CD013420. DOI: 10.1002/14651858.CD013420
Rosati MG, Peters AT. Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis. Am J Rhinol Allergy. 2016;30(1):44-47. DOI: 10.2500/ajra.2016.30.4252
Sedaghat AR, Phipatanakul W, Cunningham MJ. Characterization of aeroallergen sensitivities in children with allergic rhinitis and chronic rhinosinusitis. Allergy Rhinol (Providence). 2014;5(3):143-145. DOI: 10.2500/ar.2014.5.0102
Bousquet J, Schunemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI: 10.1016/j.jaci.2019.06.049
Castro-Rodríguez JA. The Asthma Predictive Index: a very useful tool for predicting asthma in young children. J Allergy Clin Immunol. 2010;126(2):212-216. DOI: 10.1016/j.jaci.2010.06.032
Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190. DOI: 10.2500/ajra.2012.26.3762
Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897-906. DOI: 10.1183/09031936.00121308
Dixon AE, Castro M, Gerald LB, Holbrook JT, Henderson RJ, Casale TB, et al. Effect of intranasal corticosteroids on allergic airway disease in asthma. J Allergy Clin Immunol Pract. 2017;5(4):1125-1128.e3. DOI: 10.1016/j.jaip.2017.02.022
Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372(5):456-463. DOI: 10.1056/NEJMcp1412282
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538.e13. DOI: 10.1016/j.jaci.2017.06.014
Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855-859. DOI: 10.1111/j.1398-9995.2006.01068.x
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948. DOI: 10.1111/j.1398-9995.2007.01451.x
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049-1057. DOI: 10.1016/S0140-6736(08)61446-4
Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med. 2006;100(2):354-362. DOI: 10.1016/j.rmed.2005.05.012
Lee TJ, Fu CH, Wang CH, Huang CC, Huang CC, Chang PH, et al. Impact of chronic rhinosinusitis on severe asthma patients. PloS One. 2017;12(2):e0171047. DOI: 10.1371/journal.pone.0171047
Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. DOI: 10.1016/j.rmed.2020.105947
Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12(2):272-276. DOI: 10.1111/j.1440-1843.2006.00964.x
American Lung Association-Asthma Clinical Research Centers’ Writing Committee, Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, et al. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. J Allergy Clin Immunol. 2015;135(3):701-709.e5. DOI: 10.1016/j.jaci.2014.06.038
Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747-754. DOI: 10.1080/14712598.2018.1492540
Smith KA, Pulsipher A, Gabrielsen DA, Alt JA. Biologics in chronic rhinosinusitis: an update and thoughts for future directions. Am J Rhinol Allergy. 2018;32(5):412-423. DOI: 10.1177/1945892418787132
Liang B, Yi Q, Feng Y. Association of gastroesophageal reflux disease with asthma control. Dis Esophagus. 2013;26(8):794-798. DOI: 10.1111/j.1442-2050.2012.01399.x
Thakkar K, Boatright RO, Gilger MA, El-Serag HB. Gastroesophageal reflux and asthma in children: a systematic review. Pediatrics. 2010;125(4):e925-e930. DOI: 10.1542/peds.2009-2382
Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128(3):1128-1135. DOI: 10.1378/chest.128.3.1128
Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, et al. Lansoprazole is associated with worsening asthma control in children with the CYP2C19 poor metabolizer phenotype. Ann Am Thorac Soc. 2015;12(6):878-885. DOI: 10.1513/AnnalsATS.201408-391OC
Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516-554. DOI: 10.1097/MPG.0000000000001889
Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest. 2018;153(2):515-527. DOI: 10.1016/j.chest.2017.08.029
Cusack RP, Gauvreau GM. Pharmacotherapeutic management of asthma in pregnancy and the effect of sex hormones. Expert Opin Pharmacother. 2021;22:339-349. DOI: 10.1080/14656566.2020
Wang H, Li N, Huang H. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Can Respir J. 2020;2020:9046842. DOI: 10.1155/2020/9046842
Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand. 2015;94(8):797-819. DOI: 10.1111/aogs.12680
Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517-1525. DOI: 10.1001/jama.2010.479
Takemoto MLS, Menezes MO, Andreucci CB, Knobel R, Sousa LAR, Katz L, et al. Maternal mortality and COVID-19. J Matern Fetal Neonatal Med. 2020;16:1-7. DOI: 10.1080/14767058.2020.1786056
Wang G, Murphy VE, Namazy J, Powell H, Schatz M, Chambers C, et al. The risk of maternal and placental complications in pregnant women with asthma: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2014;27(9):934-942. DOI: 10.3109/14767058.2013.847080
Robijn AL, Murphy VE, Gibson PG. Recent developments in asthma in pregnancy. Curr Opin Pulm Med. 2019;25(1):11-17. DOI: 10.1097/MCP.0000000000000538
Namazy JA, Schatz M. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. Semin Respir Crit Care Med. 2018;39(1):29-35. DOI: 10.1055/s-0037-160621
Nair P, Prabhavalkar KS. Monitoring asthma in pregnancy: diagnosis and treatment. Clin Pulmonary Med. 2020;27(3):67-72. DOI: 10.1097/CPM.0000000000000358
Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405-1411. DOI: 10.1056/NEJM199711133372001
Cossette B, Beauchesne MF, Forget A, Lemiere C, Larivee P, et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 2014;112(5):459-464. DOI: 10.1016/j.anai.2014.02.010
Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407-412. DOI: 10.1016/j.jaci.2014.08.025
Kemp M, Newman J, Challis J, Jobe A, Stock S. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240-259. DOI: 10.1093/humupd/dmv047
Lim A, Stewart K, Konig K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45(7-8):931-945. DOI: 10.1345/aph.1P764
Health topics: adolescent health [Internet]. World Health Orgnization; 2010. Disponible en: https://www.who.int/health-topics/adolescent-health/#tab=tab_1
Bitsko MJ, Everhart RS, Rubin BK. The adolescent with asthma. Paediatr Respir Rev. 2014;15(2):146-153. DOI: 10.1016/j.prrv.2013.07.003
De Benedictis D, Bush A. Asthma in adolescence: Is there any news? Pediatric pulmonology. 2017;52(1):129-138. DOI: 10.1002/ppul.23498
Michaud PA, Suris JC, Viner R. The adolescent with a chronic condition. Part II: healthcare provision. Arch Dis Child. 2004;89(10):943-949. DOI: 10.1136/adc.2003.045377
Roberts G, Vázquez-Ortiz M, Knibb R, Khaleva E, Alviani C, Angier E, et al. EAACI guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy. 2020;75(11):2734-2752. DOI: 10.1111/all.14459
Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in the elderly: Current understanding and future research needs-a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(Suppl 3):S4-S24. DOI: 10.1016/j.jaci.2011.06.048
González-Díaz SN, Villarreal-González RV, de Lira-Quezada CE, Guzmán-Avilan RI. Outcome measures to be considered on asthma in elderly. Curr Opin Allergy Clin Immunol. 2019;19(3):209-215. DOI: 10.1097/ACI.0000000000000525
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. DOI: 10.1016/j.jaci.2020.04.006
Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2002226. DOI: 10.1183/13993003.02226-2020
Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci Rep. 2020;10(1):21805. DOI: 10.1038/s41598-020-77791-8
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106-1120. DOI: 10.1016/S2213-2600(20)30415-X
Izquierdo JL, Almonacid C, González Y, Del Río-Bermúdez C, Ancochea J, Cárdenas R, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3);2003142. DOI: 10.1183/13993003.03142-2020
Peters MC, Sajuthi S, Deford P, Christenson S, Ríos CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83-90. DOI: 10.1164/rccm.202003-0821OC
Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155-168. DOI: 10.1016/j.resinv.2019.12.005
Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203-206.e3. DOI: 10.1016/j.jaci.2020.04.009
Domingo C, Pomares X, Amengual M, Oller M. Successful withdrawal of omalizumab in a patient with severe asthma: free IgE as a possible biomonitor. Eur J Inf Syst. 2014;12(2):389-393. DOI: 10.1177/1721727X1401200217
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751 e7. DOI: 10.1016/j.jaci.2018.09.033
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46-59. DOI: 10.1016/S2213-2600(18)30406-5
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2021 Revista Alergia México